Ascletis In-Licenses China Rights to an HCV Treatment from Medivir

21:58 EDT 18 Aug 2017 | ChinaBio Today

Ascletis of Hangzhou has in-licensed a third HCV treatment. Its latest acquisition is a nucleotide polymerase inhibitor from Medivir AB of Sweden. Ascletis acquired greater China rights for the antiviral, a NS5B inhibitor that has not yet started clinical trials. Ascletis' two other HCV treatments are in late-stage development, and the company hopes to market an all-oral, non-ribavirin combination HCV treatment in China soon. Ascletis made an upfront payment to Medivir and will pay milestones and royalties, though details of the agreement were not disclosed. More details....

Stock Symbol: (NSDQ: MVIR)

Share this with colleagues:

Original Article: Ascletis In-Licenses China Rights to an HCV Treatment from Medivir


More From BioPortfolio on "Ascletis In-Licenses China Rights to an HCV Treatment from Medivir"

Quick Search


Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Polymerase Chain Reaction (PCR)
PCR (Polymerase Chain Reaction) uses the ability of DNA polymerase (enzymes that create DNA molecules by assembling nucleotides, the building blocks of DNA. These enzymes are essential to DNA replication and usually work in pairs to create two ident...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...